HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

(-)-Salbutamol

HCID 123600
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
34391-04-3
Standard SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N
Molecular formula
C13H21NO3
Average molar mass
239.31 g/mol
Monoisotopic mass
239.15214353

Overview

(R)-salbutamol is an albuterol.

Names & identifiers

Preferred name
(-)-Salbutamol
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
English name
Levalbuterol
Molecular formula
C13H21NO3
Molecular weight
239.31

Names & synonyms

LevalbuterolLevosalbutamol(-)-Salbutamol34391-04-3(R)-salbutamol(-)-AlbuterolR-Salbutamol4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolEDN2NBH5SSASF-1096CHEBI:8746DTXSID80187964
Show more names
LEVALBUTEROL HCLSalbutamolr-albuterolLevalbutreol(L)-ALBUTEROLR-SALBUTAMOL HCLLEVOSALBUTEROLHCL
levosalbutamolum4-((1R)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenolAlbuterol (r)-Levalbuterol InhalationRefChem:56698Hydrochloride, LevalbuterolHydrochloride, LevosalbutamolDTXCID40110455

Database identifiers

CAS
34391-04-3
PubChem CID
123600
DTXSID
DTXSID80187964
ChEMBL
CHEMBL1002
ChEBI
CHEBI:8746
UNII
EDN2NBH5SS
EC Number
608-983-3
Nikkaji
J428.072E

Properties

Computed structural properties

XLogP
0.3
Topological polar surface area
72.7 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
4
Rotatable bonds
5
Heavy atoms
17
Formal charge
0
Complexity
227

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists
Collision Cross Section153.47 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Boiling point
433.5 · 433.5±40.0 °C(Predicted)
Density
1.152 · 1.152±0.06 g/cm3(Predicted)
pka
9.99 · 9.99±0.31(Predicted)
InChI
InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
InChIKey
NDAUXUAQIAJITI-PLAQIDKDNA-N
SMILES
C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|
CAS DataBase Reference
34391 · 34391-04-3(CAS DataBase Reference)
FDA UNII

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1 item

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

Safety data

hs_code
2922509090
risk_code
22
hazard_code
Xn
safety_code
36

Chemistry & industry

Pharmacology

Protein Bindingplasma protein binding is relatively low.
PharmacodynamicsIt acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
Mechanism of Action · 1 item

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Biological Half-Life3.3 - 4 hours
Metabolism/Metabolites · 2 items

Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6 items

EDN2NBH5SS

LEVALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.

LEVALBUTEROL

Absorption, Distribution and Excretion · 2 items

Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.

Related reactions

3 records
New reaction record
HRID 1455720 reaction equation
HRID 1455720As product
HRID 2375770 reaction equation
HRID 2375770As product
HRID 2375771 reaction equation
HRID 2375771As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
2 NBH5SS · EDN2NBH5SS
Comptox DTXSID
80187964 · DTXSID80187964
Protein binding
10 % · 10%
Excreted unchanged in urine
51 · 51-64%
Volume of distribution
2 · 2-2.5(L/kg)
Biological half-life
4 · 4-6 / Unchanged
Hazard Codes
Xn
Risk Statements
22 · 22
Safety Statements
36 · 36
HS Code
2922509090 · 2922509090

excreted into the urine.

Uses & manufacturing

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
Applications · 4 items

DescriptionSalbutamol is a bronchodilator medication that eases muscle tension in the airways adjoining with the lungs and enhances the flow of air circulating through the lungs. It is a short-acting medication that is used in the treatment of acute bronchopulmonary disorders which may include chronic obstructive pulmonary disorders (COPD), and chronic instances of bronchospasm resultant of acute bronchitis and bronchial asthma. It can also be used for the prophylactic treatment of training-induced bronchospasm. Salbutamol indicates 29 times more selectivity for beta2 receptors as compared to beta1 receptors, which gives it a higher specificity for adrenergic receptors positioned in the heart. Salbutamol comprises a racemic combination of Sand Risomers, where the R-isomer illustrates a higher affinity (about 150 times more) than the S-isomer, which is directly linked to increased toxicity. This has also influenced the development of levalbuterol.

DescriptionLevalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.

Uses(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.

UsesSalbutamol is the β2-agonist used most commonly for the prevention and treatment of bronchospasm. I t is most commonly administered in its inhaled form by metered-dose inhaler (1–2 puffs of 100μg each) or via nebuliser in more severe cases of bronchospasm (2.5–5mg). In patients with lifethreatening asthma it may be administered i.v. as both a bolus (250μg) and infusion (3–20μgmin –1). Intravenous administration requires cardiac monitoring as tachyarrhythmias may be significant. Salbutamol may also be used in the management of hyperkalaemia, temporarily driving K+ intracellularly via stimulation of the Na+–K+ ATPase pump.

Upstream & downstream products

Upstream raw materials

Methyl 5-acetylsalicylateBorane-methyl sulfide complexPalladium hydroxidetert-ButylamineHydrogen bromide

Additional notes

DefinitionChEBI: (R)-salbutamol is an albuterol.